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Abstract
Background: Human papillomavirus (HPV) pseudovirions have recently been shown to deliver DNA efficiently in
vivo, resulting in the priming of antigen-specific CD8+ T cells in vaccinated mice. In the current study, we compare
the different preparation methods for the generation of HPV pseudovirions for their ability to efficiently infect cells.
We also compare the antigen-specific CD8+ T cell immune responses generated by different DNA delivery
methods and several commonly used forms of vaccination with that of HPV pseudovirions.
Results: We found that the preparation method of pseudovirions is important for the efficient delivery of
encapsidated DNA. We have shown that vaccination with DNA encoding model antigen ovalbumin (OVA)
delivered by HPV-16 pseudovirions was capable of generating therapeutic antitumor effects against OVA-expressing
tumor. In addition, vaccination with DNA encoding OVA delivered by HPV-16 pseudovirions generated the highest
number of OVA-specific CD8+ T cells in mice in our system compared to DNA delivered by other delivery
methods. We also found that vaccination with OVA DNA delivered by HPV-16 pseudovirions generated the highest
number of OVA-specific CD8+ T cells in mice compared to other forms of antigen-specific vaccines. Furthermore,
HPV-16 pseudovirions were capable of carrying DNA vaccine encoding clinically relevant antigen, telomerase
reverse transcriptase, to generate antigen-specific CD8+ T cell immune responses.
Conclusions: Our data suggest that DNA vaccines delivered by HPV-16 pseudovirions may be advantageous
compared to other delivery methods and other forms of antigen-specific vaccines for application to antigen-
specific immunotherapy.
Background
DNA vaccination has emerged as a promising way to
generate antigen-specific T cell immunity due to its
safety, stability, and capacity for repeated administration.
However, naked DNA vaccines suffer from limited vac-
cine potency due to poor transfection efficiency in vivo.
Therefore, an optimized and efficient delivery system
that improves the transfection efficiency of DNA vac-
cines into cells in vivo may significantly improve the
antigen-specific immunity generated by DNA vaccina-
tion for the control of virus-associated infections and/or
tumors.
We have recently introduced the use of replication-
defective human papillomavirus (HPV) pseudovirions as
a novel approach to improve naked DNA vaccine deliv-
ery in vivo [1]. DNA plasmids can be packaged into the
papillomavirus L1 and L2 capsid proteins to generate a
‘pseudovirion’ that can efficiently deliver the encapsi-
dated DNA into infected cells. The encapsulation of the
therapeutic DNA vaccine protects the DNA from
nucleases and provides efficient targeted delivery with
great stability. Additionally, because HPV pseudovirions
contain a DNA construct with genes of interest, but not
the natural HPV viral genome, they are non-replicative
and lack many of the safety concerns associated with
live viral vectors. Furthermore, neutralizing antibodies
against one type of papillomavirus pseudovirion are
usually not cross-reactive to other types of papilloma-
virus pseudovirions. The spectrum of over 100 different
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repeated boosting with different types of HPV pseudo-
virions without concern for preexisting immunity. Thus,
HPV pseudovirions represent a potentially safe gene
delivery method for clinical usage.
We previously characterized human papillomavirus
pseudovirions as an efficient delivery system for DNA
vaccines in vivo [1]. We demonstrated that vaccination
with HPV-16 pseudovirions containing a DNA vaccine
encoding model antigen, ovalbumin (OVA), (HPV-16/
OVA psV) subcutaneously generated significantly stron-
ger OVA-specific CD8+ T cell immune responses com-
pared with OVA DNA vaccination via gene gun in a
dose-dependent manner. We demonstrated that the L2
minor capsid protein was essential for the infectivity
mediated by HPV-16/OVA psV. Additionally, we
showed that papillomavirus pseudovirions are capable of
infecting DCs [1]. Furthermore, the papillomavirus L1
capsid protein activates DCs to augment the immune
response [2,3]. Thus, human papillomavirus pseudovir-
ions represent an innovative and promising delivery sys-
tem to trigger potent antigen-specific immune
responses.
In the current study, we further characterize the appli-
cation of HPV pseudovirions as an important method
for the delivery of naked DNA immunization. We com-
pared the method of preparing HPV pseudovirions for
their ability to efficiently deliver DNA to cells. In addi-
tion, we analyzed the capability of HPV pseudovirions
to deliver naked DNA to a bone marrow-derived dendri-
tic cell line. Furthermore, we compared the delivery of
DNA by HPV pseudovirions with other methods of
administration and other forms of vaccines for their
ability to generate antigen-specific CD8+ T cell immune
responses. Our data indicate that the method of prepar-
ing HPV pseudovirion is crucial for their ability to infect
cells. In addition, DNA vaccines delivered by HPV pseu-
dovirions are able to effectively be delivered to dendritic
cells, resulting in potent antigen-specific CD8+ T cell
immune responses compared to different delivery meth-
ods and other forms of vaccination. The potential clini-
cal applications of HPV pseudovirion technology for
delivery of naked DNA vaccine are discussed.
Results
HPV pseudovirions prepared by intracellular assembly
can infect cells with much greater efficiency than HPV
pseudovirions prepared by in vitro assembly
The preparation method for pseudovirions may be cru-
cial to the efficiency of DNA delivery. It has been pre-
viously shown that naked DNA can be encapsidated by
L1 and L2 capsid proteins using in vitro assembly [4,5].
The HPV structural proteins can spontaneously self-
assemble into virus-like particles (VLPs) that
morphologically resemble the native virions. These
pseudovirions generated by in vitro assembly involve the
disruption and refolding of HPV L1L2 VLPs [4,5]. In
general, the preparation of pseudovirions by in vitro
assembly is technically demanding and the pseudovirion
generated via this mechanism lacks L2, which is
required for infection. In comparison, a recent method
involving intracellular assembly of papillomaviral vectors
was shown to generate high titers of replication-defec-
tive papillomavirus pseudovirions for vaccination [6,7].
This intracellular assembly method provides packaging
of the target plasmid within an L1 and L2 capsid. The
production cell line, 293 cells, is engineered to express
high levels of SV40 large T antigen (293TT) to drive the
amplification of the target plasmid containing an SV40
origin of replication. These 293TT cells are co-trans-
fected with codon-optimized L1 and L2 capsid genes in
an expression vector that is too large for its efficient
encapsidation along with the target plasmid (which can
contain the SV40 origin of replication but it is not
required), allowing for efficient intracellular production
of HPV pseudovirions encapsidating DNA.
We therefore compared the infectivity of HPV-16
pseudovirions carrying GFP (HPV-16/GFP psV) pre-
pared by in vitro assembly with the infectivity of HPV-
16/GFP psV prepared by intracellular assembly. As
shown in Figure 1, the infectivity of HPV-16/GFP psV
prepared by in vitro assembly was significantly lower
compared to that of HPV-16/GFP psV prepared by
intracellular assembly. These data suggest that this new
method for the generation of large quantities of replica-
tion-defective HPV pseudovirions is a significantly more
efficient method in comparison to the preparation of
HPV pseudovirions by in vitro assembly.
HPV-16 pseudovirions can efficiently infect dendritic cell
line in vitro in a dose-dependent manner
We have previously demonstrated that FITC-labeled
HPV-16 pseudovirions carrying DNA encoding model
antigen ovalbumin (HPV-16/OVA psV) were able to be
taken up by CD11c+ dendritic cells in the draining
lymph nodes of vaccinated mice [1]. To determine
whether the dose of HPV pseudovirions correlates with
the infectivity of DC-1 dendritic cell line, 5 × 10
4 of
DC-1 cells/well were seeded into 24-well plates the
night before infection. The seeded DC-1 cells were then
infected with increasing amounts of HPV-16/GFP psV
(L1 protein ranging from 0 ug to 5 ug) for 72 hours and
GFP expression was examined by flow cytometry. There
was a clear correlation between percentage of GFP+
DC-1 cells and amount of L1 protein in HPV-16/GFP
psV, as demonstrated by the increase in GFP expression
in DC-1 cells with increasing amount of L1 protein in
HPV-16/GFP psV (Figure 2A). As shown in Figure 2B,
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pseudovirions carrying GFP generated from in vitro assembly. HPV-16 pseudovirions carrying GFP (HPV-16/GFP psV) were prepared using
two different methods (intracellular assembly versus in vitro assembly) as described in the Materials and Methods. For the characterization of
infectivity, 1 × 10
5 of 293TT cells were seeded to each well of a 24-well plate the day before the infection. HPV-16/GFP psV (3 × 10
9 psV
particles containing ~30 ng of pcDNA3-GFP plasmids) prepared from intracellular assembly or in vitro assembly were diluted with 1 ml of
medium, added to each well and incubated at 37°C. After 72 hours, the cells were harvested, and GFP-positive cells were analyzed by flow
cytometry analysis using a FACSCalibur flow cytometer and analyzed with CellQuest software. Uninfected cells served as a negative control. A.
Representative flow cytometry data. B. Graphical representation of the percentage of GFP+ cells. Data expressed as means ± standard deviations
(SD) are representative of at least two different experiments.
Figure 2 Infection of dendritic cells by HPV-16 pseudovirions. DC-1 cells (5 × 10
4 cells/well) were seeded into 24-well plate the night before
infection. The seeded DC-1 cells were then infected with indicated amount of HPV16-GFP pseudoviruses (total amount of L1 protein) for 72
hours and GFP-positive cells were examined by flow cytometry. A. Line graph of percentage of GFP+ cells. B. Representative flow cytometry data
of DC-1 cells infected with HPV-16/GFP psV (5 ug of L1 protein).
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protein) showed a clear shift in the peak of GFP expres-
sion compared to that of uninfected cells, indicating
that the majority of cells infected with HPV-16/GFP
psVs had significantly greater GFP expression than
uninfected cells. Thus, our data suggest that HPV pseu-
dovirions can efficiently infect dendritic cells in vitro in
a dose-dependent manner.
Treatment of tumor-bearing mice with DNA delivered by
HPV-16 pseudovirions generates therapeutic antitumor
effects
We have previously demonstrated that C57BL/6 mice
vaccinated with HPV-16 pseudovirions carrying OVA
DNA were capable of preventing tumor growth upon
challenge with OVA-expressing tumor [1]. To determine
if DNA delivered by HPV-16 pseudovirions could gener-
ate appreciable therapeutic antitumor effects, we per-
formed in vivo tumor treatment experiments. C57BL/6
mice were inoculated subcutaneously with B16/OVA
tumor cells and treated with the various vaccination
groups three days later. Mice were boosted with the
same regimen on day 10 and 17 after tumor inoculation.
As shown in Figure 3, tumor-bearing mice treated with
HPV-16/OVA psV demonstrated significantly reduced
tumor volume as compared to tumor-bearing mice trea-
ted with HPV-16 pseudovirions carrying DNA encoding
irrelevant protein (GFP) or untreated mice. Thus, our
data suggest that treatment with HPV-16 pseudovirions
carrying OVA DNA can generate therapeutic antitumor
effects against OVA-expressing tumors in tumor-bearing
mice.
Vaccination with DNA delivered by HPV-16 pseudovirions
generates the highest levels of antigen-specific CD8+ T
cell immune responses compared to vaccination with
DNA delivered by other methods
We next compared the OVA-specific CD8+ T cell
immune responses generated by vaccination with OVA-
specific DNA vaccines delivered by different methods
including intramuscular injection followed by electro-
poration, gene gun, and HPV-16 pseudovirions. As
shown in Figure 4, C57BL/6 mice vaccinated subcuta-
neously with HPV-16/OVA psV generated the highest
number of OVA MHC class I peptide (SIINFEKL)-speci-
fic CD8+ T cell immune responses among all vaccina-
tion groups. In addition, we observed that DNA vaccine
delivered by intramuscular injection followed by electro-
poration and DNA vaccine delivered by gene gun both
generated higher OVA-specific CD8+ T cell immune
responses at a higher dose of DNA (2 ug) compared to
a lower dose of DNA (50 ng). Furthermore, we observed
that delivery of DNA vaccine by HPV-16 pseudovirions
generated a significantly higher antigen-specific CD8+ T
Figure 3 In vivo tumor treatment experiment with HPV-16 pseudovirion vaccination.5 - 8w e e k so l dC 5 7 B L / 6m i c e( 5m i c ep e rg r o u p )
were injected with 1 × 10
5 B16/OVA tumor cells subcutaneously. 3 days after tumor cell injection, the mice were vaccinated with either 5 μg
(total L1 protein amount) of HPV-16/OVA, or HPV-16/GFP pseudovirions via footpad injection. The mice were boosted with the same regimen on
day 10 and 17. Tumor growth was monitored twice a week and tumor volume was calculated as described in the Material and Methods section.
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vaccine contained in the pseudovirion. These data sug-
gest that antigen-specific vaccination with DNA vaccine
delivered by pseudovirion represents one of the most
promising approaches for generating antigen-specific
CD8+ T cell immune responses compared to other
methods of delivering DNA in vivo.
HPV-16 pseudovirions generate the highest level of
antigen-specific CD8+ T cell immune responses compared
to other forms of antigen-specific vaccines
In addition to the many vaccine delivery methods that
are currently being explored, there exist many forms of
vaccination for antigen-specific immunotherapy. It is
important to evaluate the efficacy of DNA vaccines
delivered by HPV pseudovirions compared to other
forms of antigen-specific vaccines for their ability to
generate antigen-specific CD8+ T cells. We therefore
compared the antigen-specific CD8+ T cell immune
responses generated by HPV-16/OVA psV with other
forms of vaccination including peptide-based (OVA8
(aa257-264) in incomplete Freund’sa d j u v a n t( I F A )a n d
OVA30 (aa241-270) in IFA), protein-based (OVA pro-
tein in IFA), dendritic cell-based (OVA8-pulsed
BMDCs) and vaccinia viral vector-based vaccination
expressing OVA (OVA-VV). As shown in Figure 5, mice
vaccinated subcutaneously with HPV-16/OVA psV gen-
erated the highest level of OVA-specific CD8+ T cell
immune responses among all forms of OVA-specific
vaccines. These data support that antigen-specific vacci-
nation with DNA vaccine delivered by pseudovirion
generates the best antigen-specific CD8+ T cell immune
responses compared to other forms of antigen-specific
vaccines.
Figure 4 Comparison of OVA-specific CD8+ T cell responses induced by pcDNA3-OVA delivered by different methods of
administration. 5 to 8 weeks old C57BL/6 mice (5 per group) were vaccinated with HPV-16/OVA pseudovirions containing pcDNA3-OVA (50 ng)
subcutaneously (s.c.), or pcDNA3-OVA either intramuscularly (IM) by electroporation (EP) (2 ug or 50 ng) or intradermally by gene gun delivery (2
ug or 50 ng). These vaccinated mice were boosted once after 7 days with the same dose and regimen. Splenocytes were collected one week
after last vaccination, and stimulated with OVA MHC class I peptide SIINFEKL (1 ug/ml) in the presence of GolgiPlug. The OVA-specific CD8
+ T
cells were then analyzed by staining surface CD8 and intracellular IFN-g. A. Representative flow cytometry data. B. Graphical representation of the
number of OVA-specific CD8+ T cells per 3 × 10
5 splenocytes. Data expressed as means ± standard deviations (SD) are representative of at least
two different experiments.
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clinically relevant antigen to generate enhanced antigen-
specific CD8+ T cell immune responses
In order to explore whether DNA delivered by HPV
pseudovirions can be applied to clinically relevant anti-
gens, we have chosen telomerase reverse transcriptase
(TERT) (for review, see [8]). TERT is an endogenous
a n t i g e nt h a ti su s u a l l yn o te x p r e s s e di nm o s tn o r m a l
human somatic tissues but is reactivated in 85% of
tumors. Upon reactivation of telomerase in tumor
cells, TERT is processed and presented on the MHC
class I molecules of tumor cells. Hence, TERT repre-
sents an attractive target for vaccine development. We
therefore created DNA encoding calreticulin (CRT)
linked to TERT198 minigene (aa198-205, VGRNFTNL)
[9] delivered by HPV pseudovirions. CRT has been
shown to be one of the most potent intracellular tar-
geting strategies to enhance antigen-specific CD8+ T
cell immune responses in our previous study [10].
TERT198 minigene was shown to have a significantly
high avidity for binding with H-2K
b [9]. As shown in
Figure 6, mice vaccinated with HPV-16 pseudovirions
carrying CRT linked to TERT198 minigene (HPV-16-
CRT/TERT198) demonstrated significantly higher
number of TERT198-specific CD8+ T cell immune
responses compared to mice vaccinated with control
HPV-16 pseudovirions carrying CRT DNA. Thus, the
delivery system of HPV-16 pseudovirions can be
applied to other DNA vaccines targeting clinically rele-
vant antigenic systems.
Figure 5 Comparison of OVA-specific CD8+ T cell responses induced by different forms of OVA-specific vaccines.5t o8w e e k so l d
C57BL/6 mice (5 per group) were vaccinated with HPV-16 pseudovirions carrying OVA (HPV-16/OVA psV) containing pcDNA3-OVA (50 ng)
subcutaneously (s.c.), or OVA8 (aa257-264) (15 μg) in incomplete Freund’s adjuvant (IFA), or OVA30 (aa241-270) (50 μg) in IFA, or OVA protein (50
μg) in IFA s.c., or OVA8-pulsed bone marrow-derived dendritic cells (BMDC) (5 × 10
5 cells/mouse). Mice were boosted once after 7 days with the
same dose and regimen. At the time of boost, another group of naïve mice were vaccinated with OVA-expressing vaccinia viruses (OVA-VV) (1 ×
10
7 pfu) intraperitoneally. Splenocytes were collected one week after last vaccination, and stimulated with OVA MHC class I peptide SIINFEKL (1
μg/ml) at the presence of GolgiPlug. The OVA-specific CD8
+ T cells were then analyzed by staining surface CD8 and intracellular IFN-g. A.
Representative flow cytometry data. B. Graphical representation of the number of OVA-specific CD8+ T cells per 3 × 10
5 splenocytes. Data
expressed as means ± standard deviations (SD) are representative of at least two different experiments.
Peng et al. Cell & Bioscience 2011, 1:26
http://www.cellandbioscience.com/content/1/1/26
Page 6 of 11Discussion
In the current study, we found that replication-defective
HPV pseudovirions prepared by intracellular assembly
can infect cells with greater efficiency than HPV pseu-
dovirions prepared by in vitro assembly. Our data also
indicate that HPV-16 pseudovirions are capable of
infecting DC-1 dendritic cell line in vitro.W ea l s o
demonstrate that tumor-bearing mice treated with
HPV-16/OVA psV could generate therapeutic antitumor
effects against OVA-expressing tumors. In addition, we
demonstrate that HPV pseudovirions carrying DNA
encoding antigen generate the highest levels of antigen-
specific CD8+ T cell immune responses compared to
DNA delivered by other methods, including gene gun
and intramuscular injection followed by electroporation.
We also show that HPV pseudovirions generate the
highest level of antigen-specific CD8+ T cell immune
responses compared to other forms of antigen-specific
vaccines. Furthermore, HPV pseudovirions could be
used to deliver clinically relevant antigen for the genera-
tion of antigen-specific CD8+ T cell immune responses.
We observed that there is significantly higher infectiv-
ity in HPV pseudovirions generated by intracellular
assembly compared to HPV pseudovirions prepared by
in vitro assembly (Figure 1). The method of HPV pseu-
dovirion generated by intracellular assembly resembles a
system more biologically similar to the natural environ-
ment for viral assembly. Therefore, HPV pseudovirions
generated by intracellular assembly will likely be more
efficient at packaging the naked DNA into the L1 and
L2 capsid proteins versus that of HPV pseudovirions
generated by in vitro assembly. Furthermore, the confor-
mation of L1 and L2 capsid proteins in the HPV pseu-
dovirions generated by intracellular assembly will likely
be better preserved compared to HPV pseudovirions
generated by in vitro assembly. The in vitro assembly
requires the disruption of L1 and L2 capsid proteins
and refolding, a process during which may result in a
conformational change of L1 and L2 capsid proteins. It
has been shown that L2 is essential for the infectivity of
the HPV pseudovirion [1,11,12]. These factors may
account for the poorer infectivity of HPV pseudovirions
generated by in vitro assembly compared to HPV pseu-
dovirions generated by intracellular assembly.
Intradermal administration by gene gun and intramus-
cular injection followed by electroporation represent
two state-of-the-art methods for DNA vaccine delivery.
There have also been several clinical trials using gene
Figure 6 Intracellular cytokine staining followed by flow cytometry analysis for TERT198-specific CD8+ T cell immune responses.5 - 8
weeks old C57BL/6 mice were vaccinated with 5 μg of L1 protein of HPV16-CRT/TERT198, or HPV16-CRT pseudovirions via footpad injection, and
boosted twice at 4-day interval with the same regimen. 1 week after last vaccination, splenocytes were prepared and stimulated with TERT198
peptide (1 μg/ml) at the presence of GolgiPlug overnight at 37 C. The TERT198-specific CD8+ T cells were then analyzed by staining surface CD8
and intracellular IFN-g. A. Representative flow cytometry data. B. Graphical representation of the number of TERT198-specific CD8+ T cells per 3
×1 0
5 splenocytes. Data expressed as means ± standard deviations (SD) are representative of at least two different experiments.
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cines [13-15]. It is therefore important for future clinical
translation to perform a head-to-head comparison to
determine whether vaccination with HPV pseudovirion
carrying DNA will be better than the aforementioned
DNA vaccine delivery techniques at generating robust
antigen-specific CD8+ T cell immune responses. We
have previously compared the antigen-specific immune
responses generated by HPV-16-pseudovirion carrying
DNA encoding model antigen OVA with naked DNA
vaccine encoding the same model antigen administered
by gene gun [1]. Mice vaccinated with HPV-16/OVA
pseudovirions generated significantly higher number of
OVA-specific CD8+ T cell immune responses compared
to mice vaccinated with naked OVA DNA via gene gun.
In the current study, we found that vaccination with
HPV-16/OVA pseudovirions generated the highest levels
of antigen-specific CD8+ T cell immune responses com-
pared to intradermal administration via gene gun and
intramuscular injection followed by electroporation (Fig-
ure 4). Furthermore, delivery of DNA vaccine by HPV-
16/OVA pseudovirions generated a significantly greater
OVA-specific CD8+ T cell immune response even with
a lower dose of OVA DNA contained in the pseudovir-
ion. Thus, DNA vaccine delivered by pseudovirion
represents a more potent method to deliver naked DNA
vaccine in vivo compared to gene gun and electropora-
tion for their ability to generate antigen-specific immune
responses.
We also compared DNA vaccine delivered by pseudo-
virions to other forms of antigen-specific vaccines
including peptide-based vaccination, protein-based vac-
cination, dendritic cell-based vaccination and viral vec-
tor-based vaccination. We found that HPV-16/OVA
pseudovirions generated the highest level of OVA-speci-
fic CD8+ T cell immune responses compared to other
established forms of vaccination in the conditions tested
(Figure 5). However, one of the major limitations for
such kind of approach is that the forms of vaccines
compared may not be optimized, including the condi-
tions used for HPV pseudovirions. Therefore, the opti-
mization of vaccine potency for each form of the
vaccine before we perform a head-to-head comparison
in the future will generate a more comprehensive pic-
ture of the efficacy of the different vaccination
approaches compared to HPV pseudovirions.
There are several points of consideration for the clini-
cal translation of HPV pseudovirions (for review, see
[16]). For example, it is important to consider the type
of HPV pseudovirion used to deliver the DNA vaccine.
Currently, the commercially available prophylactic HPV
vaccines use virus-like particles (VLPs) that include
HPV types 16, 18, and/or HPV types 6 and 11. Vaccina-
tions with HPV VLPs have been shown to generate
potent type-specific neutralizing antibodies, which can
inhibit subsequent infection of the same type of human
papillomavirus. Thus, to avoid inhibition of vaccine effi-
cacy by pre-existing immunity with this preventive HPV
vaccine, it is essential to consider a different type of
papillomavirus for pseudovirion delivery of DNA vac-
cine. This has broad clinical implications for delivering
therapeutic HPV DNA vaccines.
Conclusions
In summary, HPV pseudovirions carrying DNA vaccine
represent a significantly more efficient system compared
to other methods of DNA vaccine delivery and other
forms of vaccination for generating antigen-specific
immunity. DNA vaccines delivered by HPV pseudovir-
ions combine both the safety features of naked DNA
and the potent infectivity of viral vector vaccines with-
out the disadvantages associated with each of them.
Thus, gene delivery using HPV pseudovirion technology
represents a potentially promising non-viral gene deliv-
ery system to trigger potent immune responses against
viral infections and cancer.
Methods
Mice
C57BL/6 mice (5-to-8-weeks old) were purchased from
National Cancer Institute (Frederick, MD, USA). All ani-
mals were maintained under specific pathogen-free con-
ditions, and all procedures were performed according to
approved protocols and in accordance with recommen-
dations for the proper use and care of laboratory
animals.
Cells
293TT cells were generated by transfecting 293T cells
with an additional copy of the SV40 large T antigen and
were kindly provided by J. Schiller (NCI, NIH) [6].
293TT cells were grown in complete Dulbecco’sm o d i -
fied Eagle medium (DMEM) (Invitrogen) containing
10% heat-inactivated fetal bovine serum (Gemini Bio-
Products). DC-1 dendritic cell line has been described
previously [17].
Peptides, antibodies and reagents
The H-2K
b-restricted Ovalbumin (OVA) peptide, SIIN-
FEKL, was synthesized by Macromolecular Resources
(Denver, CO) at a purity of ≥ 80%. FITC-conjugated rat
anti-mouse IFN-g, PE-conjugated anti-mouse CD8, PE-
Cy5 conjugated anti-mouse B220, and APC-conjugated
anti-mouse CD11c antibodies were purchased from BD
Pharmingen (BD Pharmingen, San Diego, CA). A horse-
radish peroxidase-conjugated rabbit anti-mouse immu-
noglobulin G (IgG) antibody was purchased from
Zymed (San Francisco, CA). Peptides were generated as
Peng et al. Cell & Bioscience 2011, 1:26
http://www.cellandbioscience.com/content/1/1/26
Page 8 of 11described before [18]. The following dominant minimal
CTL peptide was used: OVA aa257-264 (OVA8). In
addition, the long peptide deduced from the natural
sequence of OVA protein was used: CTL peptide OVA
aa241-270 SMLVLLPDEVSGLEQLESIINFEKLTEWTS
(OVA30). OVA protein was purchased from Sigma.
Incomplete Freund’s adjuvant was purchased from Difco
Laboratories. The vaccinia virus expressing the full-
length chicken ovalbumin (OVA) was generated using
methods described previously [19,20].
Plasmid construction
The plasmids encoding HPV16 and L1 and L2
(pShell16, p16L1 and p16L2) were kindly provided by
Dr. John Schiller (NCI). The generation of ovalbumin-
expressing plasmid (pcDNA3-OVA) and GFP-expressing
plasmid (pcDNA3-GFP) has been described previously
[21,22]. The generation of pcDNA3-CRT has been
described previously [23]. For the generation of
pcDNA3-CRT/TERT198, the synthesized oligos
(AATTCgtgggcaggaatttcactaacctttgaA and AGCTTt-
caaaggttagtgaaattcctgcccacG) were annealed and subse-
quently cloned into EcoRI and HindIII sites of
pcDNA3-CRT. The accuracy of the constructs were
confirmed by DNA sequencing.
HPV pseudovirion production
For the generation of HPV pseudovirions using in vitro
assembly, 293TT cells were transfected with pShell plas-
mid expressing codon-optimized HPV-16 L1, L2 capsid
proteins only (without pcDNA3-GFP) using previously
described protocols. The HPV structural capsid proteins
have the ability to self-assemble into virus-like particles
(VLPs). In vitro assembly into HPV pseudovirions
involves the disruption and refolding of HPV-16 L1L2
VLPs [4,5]. Briefly, 5 μg of purified HPV-16 L1L2 VLPs
were incubated in 50 mM Tris-HCL buffer (pH 7.5)
containing 150 mM NaCl, 10 mM EGTA and 20 mM
dithiothreitol (DTT) in a final volume of 100 μl at room
temperature (RT) for 30 minutes. 1 μg of pcDNA3-GFP
plasmid in 50 mM Tris-HCL buffer and 150 mM NaCl
was added to the disrupted VLPs at this step. The pre-
parations were diluted with 25 mM CaCl2 and 20%
dimethyl sulfoxide in equal volume at RT for 1 hour,
and then treated with 10 U of Benzonase Nuclease for 1
hour at RT to remove un-encapsidated plasmids.
For the generation of HPV pseudovirions by intracel-
lular assembly, HPV-16 pseudovirions were made as
described previously [6]. Briefly, 293TT cells were co-
transfected with pShell plasmid expressing codon-opti-
mized HPV-16 L1, L2 proteins and pcDNA3-GFP using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). After 44
hours incubation, the cells were harvested and washed
with Dulbecco’s PBS (Invitrogen) supplemented with 9.5
mM MgCl2 and antibiotic-antimycotic mixture (DPBS-
Mg) (Invitrogen). The cells were suspended in DPBS-
Mg supplemented with 0.5% Briji58, 0.2% Benzonase
(Novagen), 0.2% Plasmid Safe (Epicentre) at > 100 × 10
6
cells/ml and incubated at 37°C for 24 hours for capsid
maturation. After maturation, the cell lysate was chilled
on ice for 10 minutes. The salt concentration of the cell
lysate was adjusted to 850 mM and incubated on ice for
10 minutes. The lysate was then clarified by centrifuga-
tion, and the supernatant was then layered onto an
Optiprep gradient. The gradient was spun for 4.5 hours
at 16°C at 40,000 rpm in a SW40 rotor (Beckman). The
purity of HPV pseudovirions was evaluated by running
the fractions on 4-15% gradient SDS-PAGE gel. The
encapsulated DNA plasmid was quantified by extracting
encapsidated DNA from Optiprep factions followed by
quantitative real time PCR compared to serial dilutions
of naked DNA as described in [1]. The concentration of
pcDNA3 plasmid DNA and pcDNA3-OVA DNA in the
pseudovirions was determined to be approx. 6.2 ng of
DNA per 1 μg of L1 protein.
Generation of bone marrow-derived dendritic cells
Bone marrow-derived dendritic cells (BMDCs) were
generated from bone marrow progenitor cells as
described previously [24]. Briefly, bone marrow cells
were flushed from the femurs and tibiae of 5- to 8-
week-old C57BL/6 mice. Cells were washed twice with
RPMI-1640 after lysis of red blood cells and resus-
pended at a density of 1 × 10
6/ml in RPMI-1640 med-
ium supplemented with 2 mM glutamine, 1 mM sodium
pyruvate, 100 mM nonessential amino acids, 55 μM b-
mercaptoethanol, 100 IU/ml penicillin, 100 g/ml strep-
tomycin, 5% fetal bovine serum, and 20 ng/ml recombi-
nant murine GM-CSF (PeproTech, Rock Hill, NJ). The
cells were then cultured in a 24-well plate (1 ml/well) at
37°C in 5% humidified CO2. The wells were replenished
with fresh medium supplemented with 20 ng/ml recom-
binant murine GM-CSF on days 2 and 4. The cells were
harvested as indicated.
In vitro infection with HPV pseudovirions
DC-1 cells (5 × 10
4 cells/well) were seeded into 24-well
plate the night before infection. The seeded DC-1 cells
were then infected with HPV16-GFP pseudovirions (L1
protein amount ranging from 0 ug to 5 ug). 72 hours
later, the cells were analyzed for GFP expression by flow
cytometry.
Vaccination with HPV pseudovirions
C57BL/6 mice (5 per group) were vaccinated with indi-
cated HPV pseudovirions (adjusted to 5 μgL 1p r o t e i n
amount) subcutaneous injection at both hind footpads.
7 days later, the mice were boosted with indicated HPV
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antigen-specific T cell detection, mouse splenocytes
were harvested 1 week after last vaccination.
Intradermal DNA vaccination via gene gun
Gene gun particle-mediated DNA vaccination was per-
formed as described previously [25]. Gold particles
coated with pcDNA3-OVA or pcDNA3 were delivered
t ot h es h a v e da b d o m i n a lr e g i o n so fm i c eb yu s i n ga
helium-driven gene gun (Bio-Rad Laboratories Inc., Her-
cules, Calif.) with a discharge pressure of 400 lb/in
2.
C57BL/6 mice (5 per group) were immunized with 2 μg
of the DNA vaccine and boosted with the same dose
and regimen 1 week later. Splenocytes were harvested 1
week after the last vaccination.
Intramuscular DNA vaccination with electroporation
Electroporation-mediated DNA vaccination was per-
formed with methods similar to those described by
Jacob et al. [26]. C57BL/6 mice (5 per group) were
injected in the tibialis muscle of the shaved hind leg.
The appropriate concentration of DNA plasmid was
diluted in a total volume of 20 μL of PBS. DNA injec-
tion was followed immediatelyb ys q u a r ew a v ee l e c t r o -
p o r a t i o na tt h ei n j e c t i o ns i t eu s i n gaB T X 8 3 0( B T X
Harvard Apparatus, Holliston, MA). A tweezers elec-
trode was used to deliver eight pulses at 100 V for 20
ms. Vaccinated mice were boosted with the same dose
and regimen on the contralateral leg 1 week later.
Splenocytes were harvested 1 week after the last
vaccination.
Comparison Vaccinations
Peptide vaccination was performed using subcutaneous
injection of 15 μg of OVA8 (aa257-264) in incomplete
Freund’s adjuvant (IFA, Difco Laboratories) (50% v/v),
or 50 μg of OVA30 (aa241-270) in IFA in a total volume
of 200 μL [27]. Protein-based vaccination was performed
using subcutaneous injection of 50 μgo fO V Ap r o t e i n
in IFA similar to methods described previously [28].
Dendritic cell-based vaccination was performed using
subcutaneous injection with 5 × 10
5 OVA8-pulsed bone
marrow-derived dendritic cells (BMDC) similar to meth-
ods described previously [24]. Vaccinia-based vaccina-
tion was performed as described previously [29] using
intraperitoneal injection with 1 × 10
7 pfu of OVA-
expressing vaccinia viruses (OVA-VV) in 200 μLP B S .
C57BL/6 mice (5 per group) were vaccinated with
OVA8 in IFA, OVA30 in IFA, OVA protein in IFA, or
OVA8-pulsed BMDCs. Vaccinated mice were boosted 1
week later at the same dose and regimen. At the same
time of boost, a separate set of C57BL/6 mice were
intraperitoneally injected with OVA-VV. Splenocytes
were harvested 1 week after last vaccination.
Intracellular cytokine staining and flow cytometry analysis
Pooled splenocytes from each vaccination group were
incubated for 20 hours with 1 μg/ml of OVA SIINFEKL
peptide or TERT198 peptide (aa198-205) (VGRNFTNL)
[9] in the presence of GolgiPlug (BD Pharmingen, San
Diego, CA). The stimulated splenocytes were washed
once with FACScan buffer, stained with PE-conjugated
monoclonal rat antimouse CD8a (clone 53.6.7), and sub-
jected to intracellular cytokine staining using the Cyto-
fix/Cytoperm kit according to the manufacturer’s
instructions (BD Pharmingen, San Diego, CA). Intracel-
lular IFN-g was stained with FITC-conjugated rat anti-
mouse IFN-g (clone XMG1.2). Flow cytometry analysis
was performed using FACSCalibur with CELLQuest
software (BD Biosciences, Mountain View, CA).
In vivo tumor experiments
The OVA-expressing B16/OVA murine tumor model
has been described previously [30]. 5-8 weeks old
C57BL/6 mice (five mice per group) were injected with
1×1 0
5 B16/OVA tumor cells subcutaneously. 3 days
after tumor cell inoculation, the tumor-bearing mice
were treated with either 5 μg (total L1 protein amount)
of HPV16-OVA, or HPV16-GFP pseudovirions via foot-
pad injection. Tumor-bearing mice were boosted with
the same regimen on day 10 and 17 after tumor chal-
lenge. Tumor-bearing mice without treatment were
included as a control. Tumor growth was monitored
twice a week. Tumor volumes were evaluated using the
formula V(mm
3) = 3.14[largest diameter × (perpendicu-
lar diameter)
2]/6.
Statistical analysis
Data expressed as means ± standard deviations (SD) are
representative of at least two different experiments.
Comparisons between individual data points were made
by 2-tailed Student’s t test. A p value < 0.05 was consid-
ered significant.
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